STOCK TITAN
  1. Home
  2. News
  3. TEVA

Teva- Pharmaceutical Industries Ltd. - TEVA STOCK NEWS

Welcome to our dedicated news page for Teva- Pharmaceutical Industries Ltd. (Ticker: TEVA), a resource for investors and traders seeking the latest updates and insights on Teva- Pharmaceutical Industries Ltd..

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Teva- Pharmaceutical Industries Ltd.'s stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Teva- Pharmaceutical Industries Ltd.'s position in the market.

News
Teva’s New Real-World Evidence Presented at the 2024 AAN Annual Meeting Confirms Effectiveness and Patient Satisfaction for HD Chorea with the 4-week Titration Kit for AUSTEDO® (deutetrabenazine) Tablets
Rhea-AI Summary
Teva Pharmaceuticals presents final results from the Phase 4 START study at the 2024 AAN Annual Meeting, confirming the effectiveness, safety, adherence, and patient satisfaction with the 4-week Titration Kit for AUSTEDO in treating Huntington's disease chorea.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.06%
Tags
none
-
News
Teva Confirms Efficacy and Safety of AJOVY® (fremanezumab) for the Prevention of Migraine With Results from Phase 3 Trial in China
Rhea-AI Summary
Teva Pharmaceuticals' AJOVY shows efficacy in Phase 3 study, reducing migraine days significantly. The drug met primary and secondary endpoints, demonstrating superior efficacy over placebo. AJOVY also displayed a favorable safety profile. The study targeted adult Chinese patients, with positive results indicating potential global impact.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.14%
Tags
clinical trial
-
News
Teva to Host Conference Call to Discuss First Quarter 2024 Financial Results at 8 a.m. ET on May 8, 2024
Rhea-AI Summary
Teva Pharmaceutical Industries (TEVA) will release its first quarter 2024 financial results on May 8, 2024, followed by a conference call and webcast. Participants can register in advance for the call and access the webcast on Teva's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.86%
Tags
conferences earnings
News
New Pharmacokinetic Modeling Data Presented by Teva Simulates Clinical Profiles of Schizophrenia Patients Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension at SIRS 2024
Rhea-AI Summary
Teva Pharmaceuticals presents data on UZEDY, an extended-release injectable suspension of risperidone, for the treatment of schizophrenia in adults. The data includes insights on dosing conversions and strategies for switching from a long-acting injectable formulation. The presentation at the SIRS 2024 Congress highlights the efficacy and safety profile of UZEDY, emphasizing its potential to reduce relapse rates and hospitalizations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Teva and mAbxience Announce Strategic Global Licensing Agreement for Oncology Biosimilar Candidate
Rhea-AI Summary
Teva Pharmaceuticals and mAbxience collaborate on a biosimilar candidate for oncology treatment, aiming to provide cost-effective alternatives globally. The partnership supports Teva's growth strategy and mAbxience's expansion plans, emphasizing a commitment to improving healthcare access.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.35%
Tags
none
-
News
Clinical Collaboration Agreement between Teva and Launch Therapeutics to Accelerate Development of Dual-Action Asthma Rescue Inhaler (ICS-SABA/TEV-’248) Respiratory Program; Teva and Abingworth Enter Strategic Development Funding Agreement
Rhea-AI Summary
Teva Pharmaceutical Industries and Launch Therapeutics collaborate to advance Teva's Dual-Action Asthma Rescue Inhaler program TEV-‘248, with a strategic funding agreement of up to $150 million. The program aims to be the first ICS-SABA for both adult and pediatric asthma indications, combining fluticasone propionate and albuterol sulfate.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.09%
Tags
none
News
Teva and Jiangsu Nhwa Forge Strategic Partnership to Promote Patient Access to AUSTEDO® in China
Rhea-AI Summary
Teva Pharmaceutical Industries Ltd. forms a partnership with Jiangsu Nhwa Pharmaceutical Co., Ltd. to market and distribute AUSTEDO for neurodegenerative and movement disorders in China. AUSTEDO, a deuterated drug, targets chorea associated with Huntington’s disease and tardive dyskinesia, offering innovative treatment options. The partnership aims to enhance patient access to AUSTEDO in China's neuro-psychiatric health sector, leveraging Nhwa's expertise.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.1%
Tags
partnership
-
News
Teva Presents New Data Supporting Safety, Tolerability and Target Engagement of Anti-TL1A (TEV-‘574) Antibody at the 2024 ECCO Annual Meeting
Rhea-AI Summary
Teva Pharmaceuticals announces positive safety and tolerability data for anti-TL1A (TEV-'574) in inflammatory bowel disease, demonstrating rapid and sustained suppression of free TL1A. The asset shows a well-tolerated safety profile and supports ongoing Phase 2b clinical investigation. Teva also disclosed a collaboration deal with Sanofi for co-development and co-commercialization of anti-TL1A (TEV-'574) for UC and CD, with significant financial implications.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.45%
Tags
none
-
News
Teva Canada Named by Forbes as No. 1 Canadian Employer in Drugs & Biotechnology Industry
Rhea-AI Summary
Teva Canada Limited, a subsidiary of Teva Pharmaceutical Industries Ltd., has been named to Forbes list of Canada’s Best Employers 2024, ranking No. 1 of Drugs & Biotechnology employers and No. 28 of 300 overall employers. Forbes and Statista Inc. conducted independent surveys of over 40,000 Canada-based employees from companies employing at least 500 people in all industry sectors, with over 900,000 employer evaluations considered.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.9%
Tags
none
News
Teva Reports Growth in Fourth Quarter and Full Year 2023
Rhea-AI Summary
Teva Pharmaceutical Industries Ltd. reported a 7% increase in local currency terms for 2023 revenues of $15.8 billion compared to 2022. AUSTEDO® exceeded $1.2 billion in annual revenues, up 28% from 2022. The company expects strong growth to continue in 2024 with expected revenues of ~$1.5 billion. AJOVY® had global annual revenues of $435 million, up 16% from 2022. The generics business stabilized, with back-to-revenue growth in Q4 2023. The ongoing net debt reduction reduced to $16.6 billion as of December 31, 2023. The company's pivot to growth strategy is in action, with Teva api intended divestiture to focus on core business strengths and capital allocation towards growth engines and innovation. The company also entered into exclusive collaborations with Sanofi and Royalty Pharma, and a license agreement with Biolojic Design for potential treatments of Atopic Dermatitis and Asthma.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.15%
Tags
none
Stock TEVA logo
Teva- Pharmaceutical Industries Ltd.

NYSE:TEVA

TEVA Rankings

#622 Ranked by Market Cap
#2611 Ranked by Stock Gains
N/A Ranked by Dividends

TEVA Stock Data

15.63B
1.12B
53.13%
1.03%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Israel
P O B 3190

About TEVA

Teva Pharmaceutical Industries Ltd. is an Israeli multinational pharmaceutical company with headquarters in Tel Aviv, Israel. It specializes primarily in generic drugs, but other business interests include active pharmaceutical ingredients and, to a lesser extent, proprietary pharmaceuticals.